Empirical investigations have confirmed GSK-3β′s involvement in a wide spectrum of malignancies, including prostate, colorectal, gastric, pancreatic, liver, ovarian, osteosarcoma, leukemia, non-small cell lung, bladder, thyroid, glioma, kidney cancers, and other malignant tumors. This evidence concerns the gene GSK3B and cancer.